Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Merck & Co. Inc. (MRK)

84.55   -0.27 (-0.32%) 11-14 16:02
Open: 84.92 Pre. Close: 84.82
High: 85.18 Low: 83.7
Volume: 7,222,570 Market Cap: 217054M
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 85.28 - 85.729 85.729 - 86.111
Low: 82.629 - 83.141 83.141 - 83.577
Close: 83.707 - 84.578 84.578 - 85.319

Technical analysis

as of: 2019-11-14 4:31:18 PM
Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time.
Target: Six months: 101.90     One year: 119.01
Support: Support1: 82.92    Support2: 80.25
Resistance: Resistance1: 87.24    Resistance2: 101.90
Pivot: 84.05
Moving Average: MA(5): 84.07     MA(20): 83.83
MA(100): 83.94     MA(250): 80.74
MACD: MACD(12,26): 0.07     Signal(9):
Stochastic oscillator: %K(14,3): 60.24     %D(3): 54.41
RSI: RSI(14): 52.86
52-week: High: 87.35  Low: 70.89  Change(%): 13.0
Average Vol(K): 3-Month: 811034  10-Days: 765591

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
MRK has closed below upper band by 40.2%. Bollinger Bands are 4.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 15 Nov 2019 10:42:35 +0000
What's Bristol-Myers Squibb's Fair Stock Price Estimate Based On Expected 2019 Earnings?

Thu, 14 Nov 2019 07:33:28 +0000
AZN:FDA Accepts Regulatory Submission For Selumetinib In Neurofibromatosis Type1

Thu, 31 Oct 2019 04:09:08 +0000
Despite Key Patent Losses Roche Could Add $5 Billion In Sales Over The Next 3 Years

Tue, 12 Nov 2019 08:57:14 +0000
Roche's New Oncology Drugs To Add $5 Billion In Sales By 2021?

Wed, 13 Nov 2019 15:49:00 +0000
Noteworthy ETF Outflows: IYH, MRK, PFE, ABBV

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Drug Manufacturers - Major
Shares Out. (M) 2550.00
Shares Float (M) 2540.00
% Held by Insiders 0.08
% Held by Institutions 78.28
Shares Short (K) 17980
Shares Short P. Month (K)

Stock Financials

EPS 3.580
Book Value (p.s.) 10.520
PEG Ratio 1.69
Profit Margin 20.26
Operating Margin 31.60
Return on Assets (ttm) 10.8
Return on Equity (ttm) 30.9
Qtrly Rev. Growth 14.9
Gross Profit (p.s.) 11.298
Sales Per Share
EBITDA (p.s.) 7.090
Qtrly Earnings Growth -2.50
Operating Cash Flow (M) 12240.00
Levered Free Cash Flow (M) 9740.00

Stock Valuations

P/E 23.62
P/E Growth Ratio
P/BV 8.04
P/S 4.75
P/CF 17.61

Dividends & Splits

Dividend 2.130
Dividend Yield 0.03
Dividend Pay Date 2019-10-07
Ex-Dividend Date 2019-09-13
Forward Dividend 2.200
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.